Scheme1. Principle of the linkage of al ysine residuea nd at hiol with succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (1;left) and the NHSfunctionalized phosphonamidate 2 (right). In contrast to maleimides, phosphonamidates are not prone to hydrolysis and thiol exchange, [12c, 23] and can deliver configurationally definedc onjugates if starting from enantiomericallypure phosphonamidates.
Introduction
The chemical fusion of proteins with other complex molecules, such as fluorescent dyes, functional peptides, therapeutically active drugs, or even other full-length proteins, can significantly expand their function, and thus, give rise to new tools in the area of cellular biology,m edical diagnostics, and targetedt herapeutics. [1] Duet ot he ease of application in modifying unengineered proteins, bifunctional chemical reagentst hat specifically modify native amino acid residues are extremely powerful compounds for the construction of complex protein conjugates. [2] Controlo ver the conjugation process can be achievedw ith hetero-bifunctional molecules that carry functional groups with distinct reactivities, which allows the coupling of two different amino acid residues in as tepwisem anner.T he prime residues targeted by such hetero-bifunctional crosslinking reagents are typicallyc ysteine and lysine due to their differences in reactivity.T he e-amino group of lysine and the Nterminus is commonly addressed with amine-reactive N-hydroxysuccinimide (NHS) esters, which demonstrate favorable reaction kinetics at almostn eutral pH, together with sufficient selectivity. [3] Most prominently,s uch NHS esters have been combined with thiol-reactive electrophilicd isulfides and various maleimide derivatives to form ar eductively cleavable disulfide bond be-Herein, the applicationo fN-hydroxysuccinimide-modified phosphonamidate building blocks for the incorporation of cysteine-selective ethynylphosphonamidates into lysine residues of proteins,f ollowed by thiol addition with small molecules and proteins, is reported. It is demonstrated that the building blocks significantly lower undesired homo-crosslinking side products that can occur with commonly applied succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) under physiological pH. The previously demonstrated stability of the phosphonamidate moiety additionally solves the problem of premature maleimideh ydrolysis, which can hamper the efficiency of subsequentt hiol addition. Furthermore, am ethod to separatet he phosphonamidate enantiomerst ob eable to synthesize protein conjugates in ad efined configurationh as been developed. Finally,t he building blocks are appliedt ot he construction of functional antibody-drug conjugates, analogously to FDA-approved,S MCC-linked Kadcyla, and to the synthesis of af unctional antibody-protein conjugate.
tween the two reactants [4] or generate asuccinimidyl-thioether bond with increased stability,respectively. [5] Despite being the most widelyu sed cysteine conjugation method, maleimide chemistry is associated with severald rawbacks. [6] First, maleimide conjugates are prone to hydrolysis, forming the ring-opened maleamic acid moiety,w hich is unreactive to sulfhydryl groups (Scheme 1). Thisi se specially problematic in the context of hetero-bifunctional crosslinking reagentsb ecause maleimides that hydrolyze during the installation step on the protein by NHS chemistry can diminish the overall conjugation yield for the final conjugate. [2, 7] Furthermore, the succinimidyl-thioether bond is prone to undergo the retro-Michael reaction, re-forming the unconjugated maleimide, which can, in turn, conjugate to othere xternal thiols thereafter (Scheme 1, left). [8] This thiol exchange reaction is especially problematic in the context of targeted therapeutics because severe side effectsc an arise from premature drug loss from the targeting unit during circulation in the blood stream. [9] As trategy to overcome this issue is to hydrolyze the maleimide residue after thiol conjugation to the open-ring form, which is not susceptible to thiol exchange. [10] However, this strategy might be limited by incomplete hydrolysis and the formation of constitutionally and stereoisomericm ixtures. [11] Furthermore, we and others have observed that maleimides can cross-react with other nucleophilic amino acid residues, such as lysine. [12] Am aleimide-based hetero-bifunctional crosslinkert hat is known for limited hydrolysis and thiol exchange, due to its sterically hindered cyclohexyl moiety,i s1, [2b, 7] which is today's most widely used reagent for the stepwise conjugation of complexp rotein structures. [2a] Amongo thers, it has been applied to the synthesis of peptide-protein conjugates, [13] hapten-carrier complexes, [14] antigen-antibody [15] and enzymeantibodyf usions, [16] therapeutically relevant immunotoxins, [17] and antibody-drug conjugates (ADCs). [18] Am ajor drawback of 1 is its hydrophobicity,which often requires the addition of cosolvents in the first reaction step. Although this problem has been partially solved by the incorporationo fasulfonica cid moietya tt he succinimidyl leaving group, [19] the remaining linker hydrophobicity in the final product can still cause aggregation and precipitation, which has been described as one of the main issues in the context of ADCs. [20] Substitution of the central cyclohexane ring with a1 ,3-dioxane structure was shown to enhance the hydrophilicity of the final conjugate. [21] Recently,w ei ntroduced unsaturated phosphonamidates for the selectivea nd irreversible modification of cysteiner esidues in proteins and antibodies. [12c, 22] We describedt he synthesis of NHS-modified ethynylphosphonamidate buildingb lock 2 and demonstrated that hydrophilic diethylene glycol substitution at the phosphonamidate ester residue could drastically increase the water solubility. [12c, 23] Here, we applied these building blocks for the synthesis of ADCs and antibody-protein conjugates and compared those to state-of-the-art 1.I nc ontrast to the maleimide residue within 1,t he phosphonamidates are stable to hydrolysis under NHS conjugation conditions. [12c] We demonstrate that ethynylphosphonamidates exhibit ah igher cysteines electivity and therebyr educe undesiredh omo-crosslinking side products at physiological pH (7.4) . Furthermore, we showedt hat NHS-phosphonamidates were able to deliver configurationally defined conjugates,i ft he enantiomersw ere separated beforehand, giving rise to linker moleculest hat enabled the construction of stable, polar,a nd more homogeneous conjugation products (Scheme 1).
Results and Discussion
We started our investigations by preparative chiral HPLC separation of the two enantiomerso fc ompound 2 that originated from the previously described Staudinger-phosphonite reaction of diethyl ethynylphosphonite and 4-azidobenzoic acid NHS ester. [12c] After successful separation with aC hiralpak IA column, elutingw ith 30 %i sopropanol in hexane, both enantiomers( + +)-and (À)-2,a sw ell as the racemic mixture, were reactedw ith the 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS) amine under basic conditions andt he functional fluorescent phosphonamidates 3 werei solated in very good yields. Next, l-glutathione was added to the triple bond and the corresponding products 4 were subjected to HPLC and 31 PNMR spectroscopic analysis( Figure1A). Similart oo ur previousobservations, [12c] we found that more than 90 %o ft he Z isomer formed upon thiol addition ( Figure 1B and Figure S1 in the Supporting Information). In addition, the Z isomerst hat originated from the reactiono ft he enantiomerically pure phosphonamidates(+ +)-and (À)-2 displayed asingleresonance in the 31 PNMR spectrum at d = 17.58 and 17.51 ppm, respectively.I nc ontrast, two resonances in the same shiftr ange were observedf or the compound that originated from the racemic mixture ( Figure 1C ). These observations clearly demonstrate that enantiomerically pure ethynylphosphonamidates can deliver configurationally defined conjugates after cysteine addition, with more than 90 %o fc onjugates in the Z configuration.
After we demonstrated that chiral NHS-modified ethynylphosphonamidate 2 was able to deliver conjugates in ad efined configuration, we continued with the evaluation of the lysine reactivity on proteins. The monoclonal antibody trastuzumab wasc hosen as af unctional, therapeutically relevant protein structure.D ifferent equivalents of the NHS esters 1 and 2 and more hydrophilic diethylene glycols ubstituted 5 were added to the antibody at ac oncentration of 1mgmL À1 in phosphate-buffered saline (PBS) at pH 7.4, containing 10 %o f DMSO to ensure solubility for all of the compounds (Figure 2A) . After purification to remove excess reagent, the reaction productsw ere analyzed by means of MS to determine the averaged egree of modification( Figure S2 ). We observed a linear correlation betweent he equivalents we applied to the antibody and the degree of protein modification for all of the tested reagents. It turnedo ut that 20 equivalents of the modi-fication reagents led to an average degree of 3.5 modifications per antibody in case of compound 1.U nder the same conditions, NHS esters 2 and 5 gave only 2.1 and 1.2 modifications per antibody,r espectively.W ea ttribute this observation to increased hydrolysis rates of the more electron-deficient aromatic NHS esters 2 and 5.T oc ompensatef or this, we also performed the reaction at higher antibody concentrationso f 4mgmL À1 .H ere, both compounds gave ag ood degree of modification of 4.6 for compound 2 and almost4for compound 5,u pon applying 20 equivalents of reagent ( Figure 2B ). However, in case of 1,t he formation of aw hite precipitate was observed and no antibody could be detected during MS analysis. Therefore, we also analyzed all reactions by means of SDS-PAGE to visualize intermolecular covalent crosslinks that might originate fromu nspecificr eactions of the thiol-reactive moiety with amino acids other than cysteine.I ndeed, we observed an increasing amount of high-molecular-weight bands with increasinge quivalents of maleimide compound 1 under our tested reactionc onditions. These bands werea bsent for all tested ethynylphosphonamidate reactions, even at high antibody concentrations of 4mgmL À1 and 20 equivalents of reagents ( Figures 2C and S3 ).
Next, we proceeded with the addition of athiol to the installed sulfhydryl acceptors. Recently,wehave shown that ethynylphosphonamidate linkages exhibit excellent properties for the construction of ADCs,s uch as high serum stabilities and in vivo efficacy. [23] As trastuzumab, modified with 1 and the thiolcontaining drugD M1, is one of the five FDA-approved ADCs, namedt rastuzumab-emtansine (brand name Kadcyla), [18, 24] we aimed to reconstruct this ADC by applying the conjugation conditions described in the previousparagraph in PBS. [25] In our case, we treated the trastuzumaba ntibodies that had previously been incubated with 5, 10, and 20 equivalents of 1, 2,a nd 5 at ac oncentration of 4mgmL À1 with 10 equivalents of DM1 with respectt ot he antibody.A ccording to our previously optimized conditions, [23] we performed the thiol addition to trastuzumab-2 and trastuzumab-5 at pH 8.5, whereas phys- iological pH was used in the case of trastuzumab-1.A fterwards, we purified the ADCs by means of size-exclusion chromatography (SEC) to remove excesst oxin and analyzed the drug-to-antibody ratio (DAR) of the constructs by means of MS ( Figure 3A and C) . Here, we faced severe aggregation and solubility issues for the ADCs that had been constructedf rom 20 equivalents of compounds 1 and 2 at pH 7.4. Hence, we were unable to measure the DAR by meanso fM S. We attribute this observation to the undesired crosslinkingt hat we have observed previously for compound 1 and to the fact that hydrophobic DM1i nc ombination with the rather hydrophobic molecules 1 and 2 drastically increases the antibody's tenden-cy to aggregate, especially for the higher DAR species. [26] Antibodies treated with 5o r1 0equivalents showedb etter behavior in terms of aggregation;h owever,h ere it was not possible to achieve higher drug loadings than that of 1o r1 .5 for 1 and 2,r espectively,u nder the conjugation conditions that have been applied here. Again,d ecreasing the antibody concentration to 1mgmL À1 improved the conjugation efficiency and led to aD AR of 2i f2 0equivalents of 1 were used, but only to a DAR of 1.2 for compound 2 ( Figure 3B) . No aggregation or precipitation,e ven at higher concentrations, were observed if the more polar di(ethylene glycol)-substituted phosphonamidate 5 was applied for the fusion of trastuzumab to DM1. These resultsa re in line with our previous observations that di(ethylene glycol) substitution at the phosphonamidate core can drastically improvet he aqueouss olubilization behavior of lipophilic drug molecules. [23] After extensive characterization of the synthesized ADCs by meanso fM S, SDS-PAGE, SEC, andh ydrophobic-interaction chromatography (HIC;F igures S5-S8), we validated the functionality of the synthesized ADCs. Therefore, we tested three trastuzumab-DM1 conjugates,s ynthesized from compounds 1, 2,a nd 5 with similar DARs of 1.4 to 1.6 in aH ER2-based cell viability assay with aH er2-overexpressing cell line (SK-BR-3) and aH er2-negative cell line as ac ontrol (MDA-MB-468). Antibody concentrations leadingt o5 0% maximal growth inhibition (IC 50 )w ere measured to be 14.9 ng mL À1 for trastuzumab-1-DM1, 16.3 ng mL À1 for trastuzumab-2-DM1, and 19.8 ng mL À1 for trastuzumab-5-DM1 ( Figure 3D) . These values are very similart op reviously determined inhibition constants of trastuzumabe mtansine of 11 ng mL À1 with SK-BR-3 cells. [27] As an additional control, trastuzumab was treated under the conjugation conditions with DM1 only,w ithout prior installation of a thiol acceptort or ule out any unspecific bindingo ft he drug to the antibody.A se xpected, this antibodyd id not show any effect on the Her2-positive cell line after purification from excess drug. Notably,n oc ytotoxicity for any of the constructs was observed on the Her2-negative cell line.
In addition, we analyzed the constructsb ym eanso fH IC, which is am ethod that enables separation of different ADC speciesb ased on the overall hydrophilicity. [28] As expected, we observed ab road peak in the HIC chromatogram, due to the broadly homogenous ADC species that typicallya rise from lysine conjugation. [29] This peak was clearly shifted towards shorterretentiontimes for more polar trastuzumab-5-DM1 relative to those of the other two tested linker systems ( Figure S8) . Because it is known that more hydrophilic ADCs are, in general,l ess prone to undesired aggregation behavior, [30] we believe that compound 5 is able to address current issues associated with the hydrophobic linker used in trastuzumabemtansine. [31] Finally,w ea lso wanted to apply our phosphonamidate buildingb locks to am ore challenging thiol-containing molecule and aimed for the synthesis of an antibody-protein conjugate. We chose our previously established eGFP mutant C70M S147C,w hichc arrieso nly one addressable cysteine residue, and incubated it in a3 .5-fold excess with trastuzumab that was preactivated with 20 equivalents of 5 at ac oncentrationo f Figure 2 . Additionofd ifferent equivalents of NHS esters 1, 2,and 5 to trastuzumab and analysis by means of MS and SDS-PAGE. A) Synthetic scheme. B) Estimation of the degree of antibodym odificationbym eans of MS analysis after incubation with 2, 5, 10, and20equivalents of the threecompounds.T op:1mg mL À1 antibody was used in conjugation,b ottom: 4mgmL À1 .S hown are meanand error from two independent experiments. *No protein masses detected. C) SDS-PAGEa nalysis of thea ntibodiest reated at 1mgmL À1 with 2, 5, 10, and 20 equivalents of the threecompounds.
ChemBioChem 2020, 21,1 13 -119 www.chembiochem.org 2019 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim 4mgmL À1 ( Figure 4A ). After conjugation and purification by means of SEC to remove unconjugated eGFP,w ec ould observe successful conjugation by meanso fS DS-PAGE (Figure 4B )a nd MS. MS analysisc learly showed that an eGFP-LC adduct had formed. Because unconjugated phosphonamidates were still detected on the HC and LC of the antibodya fter the conjugation reaction, it should be noted that the conjugation yield was lower than those in previous conjugation experiments with small-molecule thiols. However,successful conjugation was additionally confirmed by meanso fi mmunostaining experiments with the trastuzumab-eGFP constructs after fixation of either SK-BR-3 or MDA-MB-468 cells with paraformaldehyde. Here, excellent target selectivity for the Her2-receptor on the outer cell membrane could be observed fort he SK-BR-3 cell line ( Figures 4C and S9 ). This experiment again shows that antibodym odification with NHS ester 5 does not affect the antibody's performance and enables the fusion of af ull-length protein with retained functionality.
Conclusion
NHS-modified ethynylphosphonamidates were applied to the sequential coupling of lysine residues in protein structures with thiol-containing small molecules and proteins.F urthermore,e nantiomerically pure NHS-modified ethynylphosphonamidates enabled the synthesis of ac onjugate with as ingle enantiomer on phosphorus. Considering the high Z selectivity of thiol addition, this gives rise to more defined reaction products, in terms of stereochemistry,t hat would not be possible with standard maleimide chemistryb ecause as tereocenter is formed upon cysteinea ddition. The hetero-bifunctional reagent wasa lso used in the synthesis of ap hosphonamidatelinked analogue of the FDA-approved ADC Kadcyla, in which the NHS reaction was performed at physiological pH. Although these conditions delivered al ower DAR than that of the ADC currently available on the market, we were able to demonstrate the functioni nc ell viability assays and an increase in ADC polarity,i fe thylene glycol substituted phosphonamidate 5 was used. Finally,ac hallenging protein-antibody conjugate was prepared and the functionality of both parts was demon- Figure 3 . Synthesis of efficacious ADCs from trastuzumab; 1, 2,or5;and DM1.A )Synthetic scheme for ADCsynthesis from 2 or 5.B )DAR estimation of the ADCs by means of MS after the synthetic procedure, applying ap rotocolo f4mg mL À1 antibodyand 5, 10, or 20 equivalentso f1, 2,and 5,followed by incubationw ith 10 equivalents of DM1. DM1 conjugation was performed in abuffer containing 50 mm Tris at pH 8.5 for trastuzumab-2 and trastuzumab-5 and in PBS at pH 7.4 for trastuzumab-1.D ashed bar:1mg mL À1 antibodyand 20 equivalents. *No protein masses detected. C) MS analysis of the ADCs. Light (LC) and heavyc hain(HC) after DM1 conjugation (top:trastuzumab-2-DM1, bottom trastuzumab-5-DM1). #h alf-masses of the HC signals, deconvolution artefacts.D )Cell viability assay of three ADCs from 1 (green), 2 (red), and 5 (blue) and ac ontroli nw hich trastuzumab was incubated with DM1 only (orange).All constructs were purifiedb ym eanso fS EC before analysis.C onstructs weretested on an antigen-positive cellline (SK-BR-3) and an antigen-negative cellline (MDA-MB-468).
ChemBioChem 2020, 21,1 13 -119 www.chembiochem.org strated by meanso ff luorescence microscopy.T aken together, NHS-modified ethynylphosphonamidates have revealed their potentialt oi mprove current issues associatedw ith 1-based linker systems, such as homo-crosslinking duet ou nspecific maleimide addition under certain labeling conditions.
